1. Lebl J, Al Taji E, Koloušková S, a spol. Dětská endokrinologie a diabetologie. Praha: Galén, 2016: 96–103.
2. Pedicelli S, Peschiaroli E, Violi E, Cianfarani S. Controversies in the definition and treatment of idiopathic short stature (ISS). J Clin Res Pediatr Endocrinol 2009; 1: 105–15.
3. Dauber A, Rosenfeld RG, Hirschhorn JN. Genetic evaluation of short stature. J Clin Endocrinol Metab 2014; 99: 3080–3092.
4. Eggermann T, Binder G, Brioude F, et al. CDKN1C mutations: Two sides of the same coin. Trends Mol Med 2014; 20: 614–622.
5. Baron J, Sävendahl L, De Luca F, et al. Short and tall stature: A new paradigm emerges. Nat Rev Endocrinol 2015; 11: 736–746.
6. Bonafe L, Cormier-Daire V, Hall C, et al. Nosology and classification of genetic skeletal disorders: 2015 revision. Am J Med Genet Part A 2015; 167: 2869–2892.
7. Krakow D. Skeletal dysplasias. Clin Perinatol 2015; 42: 301–319.
8. Ornitz DM, Legeai-Mallet L. Achondroplasia: Development, pathogenesis, and therapy. Dev Dyn 2017; 246: 291–309.
9. Andrade AC, Jee YH, Nilsson O. New genetic diagnoses of short stature provide insights into local regulation of childhood growth. Horm Res Paediatr 2017; 88: 22–37.
10. Krakow D, Rimoin DL. The skeletal dysplasias. Genet Med 2010; 12: 327–341.
11. Shah BC, Moran ES, Zinn AR, Pappas JG. Effect of growth hormone therapy on severe short stature and skeletal deformities in a patient with combined Turner syndrome and langer mesomelic dysplasia. J Clin Endocrinol Metab 2009; 94: 5028–533.
12. Fallis A. Junqueira’s basic histology. J Chem Inf Model 2013; 53: 1689–1699.
13. Superti-Furga A, Bonafé L, Rimoin DL. Molecular-pathogenetic classification of genetic disorders of the skeleton. Am J Med Genet – Semin Med Genet 2002; 106: 282–293.
14. Marr C, Seasman A, Bishop N. Managing the patient with osteogenesis imperfecta: A multidisciplinary approach. J Multidiscip Healthc 2017; 10: 145–155.
15. Barat-Houari M, Sarrabay G, Gatinois V, et al. Mutation Update for COL2A1 gene variants associated with type II collagenopathies. Hum Mutat 2016; 37: 7–15.
16. Miyamoto Y, Matsuda T, Kitoh H, et al. A recurrent mutation in type II collagen gene causes Legg-Calvé-Perthes disease in a Japanese family. Hum Genet 2007; 121: 625–629.
17. Deng H, Huang X, Yuan L. Molecular genetics of the COL2A1-related disorders. Mutat Res Rev Mutat Res 2016; 768: 1–13.
18. Briggs MD, Wright MJ, Mortier GR. Multiple epiphyseal dysplasia, autosomal dominant. GeneReviews®, 1993.
19. Briggs MD, Wright MJ. Pseudoachondroplasia. GeneReviews®, 2004.
20. Acke FR, Malfait F, Vanakker OM, et al. Novel pathogenic COL11A1/COL11A2 variants in Stickler syndrome detected by targeted NGS and exome sequencing. Mol Genet Metab 2014; 113: 230–235.
21. Gkourogianni A, Andrew M, Tyzinski L, et al. Clinical characterization of patients with autosomal dominant short stature due to aggrecan mutations. J Clin Endocrinol Metab 2017; 102: 460–469.
22. van der Steen M, Pfundt R, Maas SJWH, et al. ACAN gene mutations in short children born SGA and response to growth hormone treatment. J Clin Endocrinol Metab 2016; 102: 1458–1467.
23. Gibson BG, Briggs MD. The aggrecanopathies; An evolving phenotypic spectrum of human genetic skeletal diseases. Orphanet J Rare Dis 2016; 11: 86.
24. Sakai LY, Keene DR, Renard M, De Backer J. FBN1: The disease-causing gene for Marfan syndrome and other genetic disorders. Gene 2016; 592: 279–291.
25. Goff C Le, Mahaut C, Wang LW, et al. Mutations in the TGFβ binding-protein-like domain 5 of FBN1 are responsible for acromicric and geleophysic dysplasias. Am J Hum Genet 2011; 89: 7–14.
26. Hasegawa K, Numakura C, Tanaka H, et al. Three cases of Japanese acromicric/geleophysic dysplasia with FBN1 mutations: a comparison of clinical and radiological features. J Pediatr Endocrinol Metab 2017; 30 (1): 117–121.
27. Wang J, Zhou J, Cheng CM, et al. Evidence supporting dual, IGF-I-independent and IGF-I-dependent, roles for GH in promoting longitudinal bone growth. J Endocrinol 2004; 180:247–255.
28. Stagi S, Azzali A, La Spina L, et al. Growth hormone axis in skeletal dysplasias. In: Restricted Growth – Clinical, Genetic and Molecular Aspects. InTech 2016 Oct 12. http://www.intechopen.com/books/restricted-growth-clinical-genetic-and-molecular-aspects/growth-hormone-axis-in-skeletal-dysplasias.
29. Li J, Dong S. The signaling pathways involved in chondrocyte differentiation and hypertrophic differentiation. Stem Cells International 2016; 2016: 2470351.
30. Deng C, Wynshaw-Boris A, Zhou F, et al. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 1996; 84: 911–921.
31. Massart F, Miccoli M, Baggiani A, Bertelloni S. Height outcome of short children with hypochondroplasia after recombinant human growth hormone treatment: a meta-analysis. Pharmacogenomics 2015; 16: 1965–1973.
32. Miccoli M, Bertelloni S, Massart F. Height outcome of recombinant human growth hormone treatment in achondroplasia children: A meta-analysis. Horm Res Paediatr 2016; 86: 27–34.
33. Vasques GA, Arnhold IJP, Jorge AAL. Role of the natriuretic peptide system in normal growth and growth disorders. Horm Res Paediatr 2014; 82: 222–229.
34. Vasques GA, Hisado-Oliva A, Funari MFA, et al. Long-term response to growth hormone therapy in a patient with short stature caused by a novel heterozygous mutation in NPR2. J Pediatr Endocrinol Metab 2017; 30: 111–116.
35. Choi WB, Seo SH, Yoo WH, et al. A Leri-Weill dyschondrosteosis patient confirmed by mutation analysis of SHOX gene. Ann Pediatr Endocrinol Metab 2015; 20:162–165.
36. Binder G. Short stature due to SHOX deficiency: Genotype, phenotype, and therapy. Horm Res Paediatr 2011; 75: 81–89.
37. von Bohlen AE, Böhm J, Pop R, et al. A mutation creating an upstream initiation codon in the SOX9 5’ UTR causes acampomelic campomelic dysplasia. Mol Genet Genomic Med 2017; 5: 261–268.
38. Machol K, Mendoza-Londono R, Lee B. Cleidocranial dysplasia spectrum disorder. GeneReviews®. Seattle (WA): University of Washington, 1993-2018. 2006 Jan 3 [updated 2017 Nov 16].
39. Kayemba-Kay’s S, Tripon C, Heron A, Hindmarsh P. Pseudohypoparathyroidism type IA subclinical hypothyroidism and rapid weight gain weight as early clinical signs. A clinical study of 10 cases. J Clin Res Pediatr Endocrinol 2016; 8: 432–438.
40. Cho SY, Jin D-K. Guidelines for genetic skeletal dysplasias for pediatricians. Ann Pediatr Endocrinol Metab 2015; 20: 187.